Vanda Pharmaceuticals (VNDA) Receivables (2010 - 2026)

Vanda Pharmaceuticals has disclosed Receivables across 17 years of filings, most recently posting $56.9 million for Q1 2026.

• Receivables for Q1 2026 came in at $56.9 million, up 27.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $56.9 million (up 27.52% YoY), and the FY2025 annual result was $54.6 million, up 15.87% from the prior year.
• Receivables came in at $56.9 million for Q1 2026 at Vanda Pharmaceuticals, up from $54.6 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $56.9 million in Q1 2026 to a low of $24.5 million in Q1 2023.
• The 5-year median for Receivables is $36.7 million (2024), against an average of $39.0 million.
• Across the five-year window, Receivables dropped 29.27% in 2022 and soared 49.77% in 2024, its largest moves.
• Vanda Pharmaceuticals' Receivables stood at $33.5 million in 2022, then rose by 1.92% to $34.2 million in 2023, then soared by 37.9% to $47.1 million in 2024, then increased by 15.87% to $54.6 million in 2025, then grew by 4.22% to $56.9 million in 2026.
• The last three Receivables figures came in at $56.9 million (Q1 2026), $54.6 million (Q4 2025), and $50.5 million (Q3 2025), per Business Quant data.